Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AvaTa: Erlotinib vs Erlotinib + Bevacizumab in EGFR+ NSCLC
NCT03126799Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2016
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03126799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126799.